- Mundipharma and Northlake International sign deal worth US$84.5 million - Mundipharma will collaborate on the development of NL-101 and receive global (excluding China) commercialization rightsCambridge, UK, 27 November 2012 – Mundipharma International Corporation Limited (Mundipharma) and Northlake International LLC announced today that they have entered into a strategic collaboration agreement to develop structurally novel – next generation alkylating agents for the treatment of haematological malignancies.
Press Release Distribution ,
Mundipharma strengthens oncology portfolio with strategic collaboration for next generation alkylating agentsSee also:things,
Mundipharma strengthens oncology portfolio with strategic collaboration for next generation alkylating agents
No comments:
Post a Comment